Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lantern Pharma Inc. (LTRN)

Lantern Pharma receives Nasdaq notice of non-compliance with market value rule

Negative Impact 5 of 5 legal/regulatory Written later

Lantern Pharma received a Nasdaq notice on September 25, 2026 saying it is out of compliance with the minimum market value of listed securities requirement of $35 million over the last 30 consecutive business days. The company has until March 24, 2027 to regain compliance, or it expects Nasdaq could begin delisting proceedings from the Nasdaq Capital Market.

Key points

  • Nasdaq notice dated September 25, 2026 cites Listing Rule 5550(b)(2) with a $35 million minimum market value requirement
  • Nasdaq also said the company does not meet Listing Rules 5550(b)(1) and 5550(b)(3)
  • Compliance period runs 180 calendar days, ending March 24, 2027
  • Regaining compliance requires a market value of at least $35 million for 10 consecutive business days

The filing

CompanyLantern Pharma Inc. (LTRN)
Form8-K, current report
Filed with the SECOct 1, 2026, 4:01 PM ET
Accession number0001493152-26-045344

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.